|
|
|
Research Overview
Our
focus is to develop better treatments for brain disorders. In
particular we are interested in the role of neuropeptides in the
regulation of critical brain processes that are disturbed in
neuropsychiatric illnesses, such as schizophrenia. Neuropeptides are
short versions of proteins (chains of amino acids) that play critical
roles in multiple aspects of normal brain function. There are dozens of
neuropeptides and learning about their function will open the door to
completely novel targets for effective medications. In order to
facilitate discovery of novel neuropeptide-based treatments, it is
vital to have effective animal models of neuropsychiatric illness.
Therefore, our laboratory also endeavors to develop novel, animal
models with enhanced validity for these illnesses. |
|
|
|
To learn more about
some of our discoveries regarding modeling human neuropsychiatric
disorders in animals click here: |
 |
|
|
|
|
| To learn more about
some of our discoveries regarding neuropeptide-based treatments click
here: |

|
|
|
|
|
|
Our
Current Collaborators:
Becky Kinkead, Emory University, Atlanta Georgia
Elliott Richelson, Mayo Clinic, Jackonsville, Florida
Steven Siegel, University of Pennsylvania
Thomas Dix,
Medical University of South Carolina
|